Special Issue "Cancers Gene Therapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 May 2013
Dr. Gabi Dachs
Mackenzie Cancer Research Group, University of Otago, Christchurch, PO Box 4345, Christchurch 8140, New Zealand
Interests: gene directed enzyme prodrug therapy (GDEPT); tumour hypoxia; nitroreductase; anti-vascular therapy; hypoxia-inducible factor 1 (HIF-1); ascorbate
Cancer gene therapy is designed to destroy tumours via the delivery of therapeutic genes to malignant cells. Why has the hype surrounding cancer gene therapy not (yet) resulted in an approved therapy? Adverse tumour characteristics, including inadequate blood supply and high interstitial fluid pressure, make cancer cells in solid tumours difficult to access. An innovative approach, covering all complicated aspects of this therapy, is required to revive the field. After all, it still has the potential to be the most selective of all cancer treatments, able to target even distant cancer deposits whilst sparing normal tissue.
This special issue aims to bring together both original studies and reviews covering novel aspects of gene therapy of cancer. We specifically like to invite articles covering the following areas:
• Novel therapeutic genes or gene/prodrug combinations
• Novel gene delivery methods, including reports on progress in systemic delivery
• Novel vectors, encompassing viral, bacterial, cellular and synthetic vectors
• Expression targeting via transcriptional regulation
• Targeting of not only tumour cells, but also stromal cells, including blood vessels and inflammatory cells
• Direct comparisons of gene therapy to current clinical therapies
• New imaging methods to determine location and extend of gene spread
• Sophisticated cell culture models able to mimic tumour conditions
• Sophisticated, and potentially humanised, animal models
• Clinical trial design
• Safety considerations and mechanisms of side effects
• Results from early clinical trials and proof of concept reports
• Patient and public perceptions of gene therapy of cancer
Dr. Gabi Dachs
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
cell culture and animal models
Last update: 21 November 2012